Why Is CORCEPT THERAPEUTICS (CORT) Stock Moving Today?

Corcept Therapeutics (CORT) surged 27.29% to $118.32 in a single session, marking its best day in nearly 16 months. The rally followed the company's second-quarter 2026 earnings report, which showed a 32% revenue increase to $256.1 million and an upward revision of its 2026 revenue guidance to $1.1, $1.2 billion. The stock's sharp rise was also supported by an upgraded price target from H.C. Wainwright and positive analyst coverage highlighting the rapid adoption of its drug Lifyorli and strong performance in existing product lines.

What Happened

Corcept Therapeutics reported Q2 2026 results that exceeded expectations, with revenue growth driven by the successful launch of Lifyorli and continued strength in its established franchises. The company raised its full-year revenue forecast, signaling confidence in its market position and product pipeline. H.C. Wainwright raised its price target to $165, citing the strong performance. The stock's upward momentum was further reinforced by coverage from multiple outlets, including Seeking Alpha and Stocktwits News, which highlighted the stock's 52-week highs and improved guidance. Anika Therapeutics also saw a similar rise, but Corcept Therapeutics remained the focal point of the biotech sector's gains.

What The Data Shows

The stock has risen 23.7% over the last eight sessions, moving from $95.65 to $118.32. Over the past 30 days, insider transactions totaled $26.3 million in sales, with no insider purchases recorded. The company’s fundamentals show a market cap of $10.1 billion, a P/E ratio of 231.2, and a trailing twelve-month revenue increase of 12.2%. Despite the recent gains, the stock remains within its 52-week range of $28.66 to $97.63, indicating a significant breakout.

What To Watch

The company is scheduled to release further updates on the status of relacorilant, which awaits a December 17, 2026 PDUFA decision. Investors should also monitor coverage breadth and any additional analyst upgrades or downgrades in the coming days.